Lupin advanced 0.8 percent to Rs 1,556.95 on BSE after the company said its US subsidiary has received final approval from US drug regulator to market a generic equivalent of Upsher-Smith Labs Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq.
The announcement was made after market hours yesterday, 10 August 2016.
Meanwhile, the S&P BSE Sensex was down 55.33 points or 0.2 percent at 27,719.55.
On BSE, so far 17,000 shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 1,567.60 and a low of Rs 1,551 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015.
Get more details here:-
Commodity Market Tips
BOOK PARTIAL PROFIT IN BHARATFIN 780 PUT , T1 ACHIEVED
ReplyDeleteEquity tips free trial
Lupin is a top performing stock of pharmaceutical industry. This post helped me to gain useful updates on it. Learn best trading tips on top performing stocks by joining epic research.
ReplyDelete